Shares of Intersect ENT Inc (NASDAQ:XENT) have received a consensus recommendation of “Hold” from the eleven research firms that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, one has given a buy rating and one has given a strong buy rating to the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $19.21.
A number of research firms recently weighed in on XENT. JPMorgan Chase & Co. downgraded shares of Intersect ENT from an “overweight” rating to a “neutral” rating and set a $19.00 price target for the company. in a research note on Thursday, October 8th. Piper Sandler boosted their price target on shares of Intersect ENT from $14.00 to $17.00 and gave the stock a “neutral” rating in a research note on Tuesday, August 4th. Oppenheimer reissued a “hold” rating on shares of Intersect ENT in a research note on Tuesday, August 4th. Canaccord Genuity reissued a “hold” rating and set a $18.00 price target on shares of Intersect ENT in a research note on Wednesday, August 5th. Finally, ValuEngine raised shares of Intersect ENT from a “buy” rating to a “strong-buy” rating in a research note on Thursday, October 1st.
Shares of NASDAQ XENT traded down $0.59 during trading on Friday, reaching $17.11. The company had a trading volume of 396,954 shares, compared to its average volume of 617,370. Intersect ENT has a 52 week low of $5.97 and a 52 week high of $31.46. The stock has a market cap of $559.53 million, a PE ratio of -8.96 and a beta of 1.30. The company has a debt-to-equity ratio of 0.72, a quick ratio of 10.29 and a current ratio of 11.28. The business’s 50 day moving average price is $17.73 and its 200-day moving average price is $15.01.
A number of large investors have recently modified their holdings of XENT. HighMark Wealth Management LLC increased its stake in Intersect ENT by 249.3% in the second quarter. HighMark Wealth Management LLC now owns 2,096 shares of the medical equipment provider’s stock valued at $28,000 after purchasing an additional 1,496 shares in the last quarter. Bank of Montreal Can acquired a new position in shares of Intersect ENT in the second quarter valued at approximately $47,000. Advisor Group Holdings Inc. acquired a new position in shares of Intersect ENT in the first quarter valued at approximately $48,000. Tower Research Capital LLC TRC boosted its holdings in shares of Intersect ENT by 436,600.0% in the first quarter. Tower Research Capital LLC TRC now owns 4,367 shares of the medical equipment provider’s stock valued at $52,000 after buying an additional 4,366 shares during the period. Finally, Maverick Capital Ltd. acquired a new position in shares of Intersect ENT in the first quarter valued at approximately $53,000. 84.32% of the stock is owned by hedge funds and other institutional investors.
Intersect ENT Company Profile
Intersect ENT, Inc, a drug delivery company, researches and develops products for the treatment of patients with ear, nose, and throat conditions in the United States. The company offers PROPEL and PROPEL mini drug releasing implants for patients undergoing sinus surgery to treat chronic sinusitis; and PROPEL Contour, a steroid releasing implant to frontal and maxillary sinus ostia, or openings, of the dependent sinuses.
Featured Story: How to calculate compound interest
Receive News & Ratings for Intersect ENT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT and related companies with MarketBeat.com's FREE daily email newsletter.